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Substance P as an Immunomodulatory Neuropeptide
in a Mouse Model for Autoimmune Hair Loss
(Alopecia Areata)
Frank Siebenhaar1,2, Andrey A. Sharov1, Eva M.J. Peters3, Tatyana Y. Sharova1, Wolfgang Syska1,2,
Andrei N. Mardaryev1, Pia Freyschmidt-Paul4, John P. Sundberg5, Marcus Maurer2 and
Vladimir A. Botchkarev1,6
Alopecia areata (AA) is an autoimmune disorder of the hair follicle characterized by inflammatory cell infiltrates
around actively growing (anagen) hair follicles. Substance P (SP) plays a critical role in the cutaneous
neuroimmune network and influences immune cell functions through the neurokinin-1 receptor (NK-1R). To
better understand the role of SP as an immunomodulatory neuropeptide in AA, we studied its expression and
effects on immune cells in a C3H/HeJ mouse model for AA. During early stages of AA development, the number
of SP–immunoreactive nerve fibers in skin is increased, compared to non-affected mice. However, during
advanced stages of AA, the number of SP-immunoreactive nerves and SP protein levels in skin are decreased,
whereas the expression of the SP-degrading enzyme neutral endopeptidase (NEP) is increased, compared to
control skin. In AA, NK-1R is expressed on CD8þ lymphocytes and macrophages accumulating around affected
hair follicles. Additional SP supply to the skin of AA-affected mice leads to a significant increase of mast cell
degranulation and to accelerated hair follicle regression (catagen), accompanied by an increase of CD8þ cells-
expressing granzyme B. These data suggest that SP, NEP, and NK-1R serve as important regulators in the
molecular signaling network modulating inflammatory response in autoimmune hair loss.
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INTRODUCTION
Alopecia areata (AA) is an autoimmune disorder of the hair
follicle (HF) characterized by intra- and perifollicular
inflammatory cell infiltrates consisting of CD4þ and
CD8þ T lymphocytes, macrophages, and Langerhans cells
that target HF keratinocytes, melanocytes, and dermal papilla
fibroblasts (Shapiro and Madani, 1999; McDonagh and
Messenger, 2001; McElwee et al., 2003; Paus et al., 2003,
2005; Hordinsky and Ericson, 2004). Aberrant expression of
human leukocyte antigen class I and II antigens occurs in
keratinocytes of the HF bulb leading to the autoimmune
attack by CD8þ T lymphocytes and followed by the
development of inflammatory cell infiltration in and around
the HFs (Gilhar et al., 1998, 1999; Hoffmann, 1999).
Cytokines secreted by inflammatory cells (tumor necrosis
factor-a, IL-1b, IFNg) stimulate premature HF involution
(catagen) followed by hair loss (Hoffmann, 1999; Hordinsky
and Ericson, 2004; Paus et al., 2005).
In about 20% of aged C3H/HeJ mice, AA develops
spontaneously and affects the HF in its cyclic portion (above
the bulb region to just below the level of the sebaceous gland)
(Sundberg et al., 1995a, b; McElwee et al., 2003; Sundberg and
King, 2003). The C3H/HeJ mouse model for AA shares many
features of the human condition, with minor variations in the
location of AA lesions and in the expression patterns of major
histocompatibility complex I class antigens (Freyschmidt-Paul
et al., 1999a; McElwee and Hoffmann, 2002). In non-affected
C3H/HeJ mice, AA may be induced by grafting skin from
affected animals (McElwee et al., 1998). It was shown in
human skin/Scid model that AA can be induced by the transfer
of T cells isolated from affected skin that recognize a hair
follicle autoantigen, suggesting that AA is a T-cell-mediated
disease (Gilhar et al., 1998; Gilhar and Kalish, 2006).
The murine HF is richly innervated by sensory nerve fibers
expressing the neuropeptide substance P (SP) that are located
in close vicinity to the HF bulge region, a specialized
HF compartment containing stem cell populations (Peters
et al., 2001). Cutaneous SP expression and the number of
See related commentary on pg 1289
& 2007 The Society for Investigative Dermatology www.jidonline.org 1489
ORIGINAL ARTICLE
Received 6 November 2005; revised 23 August 2006; accepted 5 October
2006; published online 1 February 2007
1Departments of Dermatology, Pathology and Laboratory Medicine, Boston
University School of Medicine, Boston, Massachusetts, USA; 2Department of
Dermatology and Allergy, University Medicine-Charite´, Humboldt University
of Berlin, Berlin, Germany; 3Department of Internal Medicine,
Psychoneuroimmunology, University Medicine-Charite´, Humboldt University
of Berlin, Berlin, Germany; 4Department of Dermatology, Philipp University
Marburg, Marburg, Germany; 5The Jackson Laboratory, Bar-Harbor, Maine,
USA and 6Laboratory of Skin Development, Regeneration and
Carcinogenesis, Medical Biosciences, School of Life Science, University of
Bradford, Bradford, UK
Correspondence: Dr Vladimir A. Botchkarev, Department of Dermatology,
Boston University School of Medicine, 609 Albany Street, Boston,
Massachusetts 02118, USA. E-mail: vladbotc@bu.edu
Abbreviations: AA, alopecia areata; HF, hair follicle; SP, substance P;
NEP, neutral endopeptidase; NK-1R, neurokinin-1 receptor
SP-immunoreactive nerve fibers are significantly increased
during the early active growth phase (anagen II–III) of the
murine hair cycle (Paus et al., 1994; Peters et al., 2001). SP
was shown to act as a growth factor for cultured keratinocytes
(Tanaka et al., 1988), and treatment of mice with SP induces
anagen in resting HFs and promotes anagen progression in
denervated, organ cultured murine skin (Paus et al., 1994;
Peters et al., 2001).
By contrast, in fully developed growing mouse HFs
(anagen VI), SP treatment induces a deleterious perifollicular
neurogenic inflammation with subsequent premature regres-
sion (catagen) of affected HFs (Arck et al., 2003). A similar
perifollicular neurogenic inflammatory response can be
observed after exposure of mice to stress (Arck et al., 2003;
Arck et al., 2005), and this response can be suppressed by
additional treatment with neurokinin-1 receptor (NK-1R)
antagonists and nerve growth factor neutralizing antibodies
(Arck et al., 2001, 2003; Peters et al., 2005). Interestingly in
this context, the link between AA and stress is described in
humans (Gupta et al., 1997; Misery and Rousset, 2001).
Human HFs affected by AA are innervated by SP-immuno-
reactive nerve fibers, which may modulate the perifollicular
immune response (Hordinsky and Ericson, 1996, 2004).
Numerous data suggest that SP via binding to the NK-1R
plays an important immunomodulatory role in the skin by
influencing the function of immunologic effector cells
involved in AA pathogenesis (CD4þ and CD8þ lympho-
cytes, macrophages, and mast cells,) (reviewed by Scholzen
et al., 1998; Katayama et al., 2001; Legat et al., 2002;
Steinman, 2004). During the inflammatory response, SP
elicits local vasodilatation and recruitment of immune cells
into inflammation sites and can stimulate cytokine secretion
from these cells (reviewed by (Legat et al., 2002; O’Connor
et al., 2004)). A similar response is observed in stressed and
SP-treated healthy murine skin (Arck et al., 2001, 2003;
Peters et al., 2005). However, roles for SP in the pathogenesis
of AA, as well as systematic analysis of neuroimmune
interactions in AA lesions have not been performed so far.
To better understand the immunomodulatory role of SP in
AA, we studied the expression and the effects of SP on
immune cells in C3H/HeJ mice affected by AA. We analyzed
the levels of SP protein and the number of SP-immuno-
reactive nerve fibers in AA-affected skin, as well as the
expression of the SP-degrading enzyme neutral endopepti-
dase (NEP) as compared to non-affected skin. We also
analyzed NK-1R expression on CD8þ cells and macro-
phages accumulating around HFs in skin affected by AA.
Finally, we performed prolonged treatment of AA-affected
mice to analyze SP effects on AA skin and immune cells.
With this approach, we aim to demonstrate that SP is an
important player in the molecular signaling network regulat-
ing the inflammatory response in autoimmune hair loss.
RESULTS
Number of SP-immunoreactive nerve fibers in skin affected
by AA fluctuates with progression of the disease
To determine whether SP expression is changed in AA-
affected skin, the number of SP-immunoreactive nerve fibers
assessed by immunohistochemistry was compared between
anagen VI skin samples collected from mice at early and
advanced stages of AA development, as well as from non-
affected C3H/HeJ mice (Figure 1). Consistent with our
previous data (Peters et al., 2001), SP-immunoreactive nerve
fibers were seen in close vicinity to and occasionally inside
the epidermis of unaffected control skin, as well as in the
interfollicular dermis (Figure 1a and d). In C3H/HeJ mice at
early stages of AA development, the number of intra/
subepidermal and dermal SP-immunoreactive nerve fibers
was significantly increased (Po0.05), compared to non-
affected mice (Figure 1b, e, and g).
By contrast, a significant decrease (Po0.01) in the number
of SP-immunoreactive nerve fibers was seen in the skin of
mice at advanced stages of induced AA (Figure 1c, f, and g),
as well as in mice with spontaneous AA (data not shown).
Also, in skin lesions of mice with advanced AA, SP protein
levels determined by ELISA were significantly reduced
compared to control mice not affected by AA (73.1þ
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Figure 1. Immunohistochemistry of SP in skin affected by AA. Full-thickness
samples of anagen VI skin taken from C3H/HeJ mice at early and advanced
stages of AA development and from non-affected control mice were
embedded and processed for SP immunohistochemistry. (a and d) Presence of
SPþ nerve fibers in the (a) epidermis and (d) dermis of control skin (arrows).
(b and e) Number of (b) epidermal and (e) dermal nerve fibers is increased in
skin at early stage of AA (arrows). (c and f) Lack of SPþ nerve fibers in the
(c) epidermis and (f) dermis of mice at advanced stage of AA. Cell nuclei are
counterstained with Hoechst 33342. (g) Immunohistomorphometry of the
cutaneous SPþ nerve fibers in the control and AA-affected mice. Statistical
analysis is performed using Student’s t-test (means7SEM, *Po0.05,
**Po0.01). Bar¼20 mm. Abbreviations: DER – dermis, EP – epidermis.
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10.6 pg/ml vs 215.9þ 28.7 pg/ml, respectively, Po0.01).
Thus, these data suggested that intraneuronal expression of
SP significantly fluctuates in skin affected by AA, increasing
during the early stages and decreasing during advanced
stages of the disease.
NEP expression is increased in skin affected by AA
To test whether levels of NEP, an SP-degrading enzyme that
limits SP activity (Grady et al., 1997; Olerud et al., 1999), are
changed in AA-affected skin, we assessed the expression of
NEP in AA-affected and non-affected skin by RT-PCR and
immunohistology (Figure 2). By RT-PCR, the expression of
NEP messenger RNA was markedly increased in anagen VI
skin affected by AA, compared to control anagen VI skin
(Figure 2a). Increased levels of NEP transcripts were seen in
both spontaneous and induced AA at advanced stages of the
disease (Figure 2a). By immunohistochemistry, only weak
expression of NEP was seen in the control skin and NEP
expression was virtually absent from the HF outer root sheath
of anagen VI hair follicles (Figure 2b). By contrast, skin of
mice with spontaneous or induced AA at advanced stages
exhibited pronounced NEP expression, which was found to
be substantially increased in the HF outer root sheath (Figure
2c). In these samples, NEP expression was also increased in
the interfollicular epidermis (data not shown) and was
additionally seen in the proximal inner root sheath of the
HFs affected by AA (Figure 2c). These data suggest that NEP
as an SP-degrading enzyme may contribute to the reduction
of SP levels and activity in skin at advanced stages of AA
development.
SP treatment promotes hair follicle regression, stimulates mast
cell degranulation, and differentially affects the number of
immune cells in AA
To explore whether SP release is involved in the maintenance
and severity of AA lesions, agarose beads soaked either with
SP or with normal mouse serum (control) were implanted into
the skin of mice affected by AA. This or similar models were
used previously in hair research for studying the long-term
effects of biologically active peptides that are released slowly
into the skin from implanted beads (Botchkarev et al.,
1999a, b, 2001; Paus et al., 1994; Peters et al., 2001). Given
that SP after intracutaneous administration is rapidly de-
graded by NEP (Scholzen et al., 1998), the goal of using this
model was also to avoid repeated injections of SP into the
skin which may cause additional inflammation in mice
affected by AA.
In skin samples examined 4 weeks after SP treatment, the
percentage of catagen HFs was significantly increased,
compared to control skin (Figure 3a), suggesting that excess
of SP supply to the skin in AA promoted HF regression, as it
has previously been observed after capsaicin treatment or
under stress (Maurer et al., 1997; Arck et al., 2003). Also, SP
administration was accompanied by a significant increase
(Po0.01) in the percentage of mast cells exhibiting signs of
extensive degranulation, whereas the percentage of non-
degranulated mast cells was significantly (Po0.01) reduced,
compared to controls (Figure 3b and d). This observation
indicates massive neurogenic inflammation, as it has
previously been observed in the close vicinity of prematurely
regressing hair follicles after capsaicin treatment or under
stress (Maurer et al., 1997; Arck et al., 2003).
In addition, CD8þ lymphocytes in AA-affected skin were
found to be significantly increased (Po0.05) after SP
treatment both inside and outside of HFs, compared to
vehicle-treated skin (Figure 3e–g). By contrast, the number of
CD4þ lymphocytes and macrophages was not affected by
SP treatment (Figure 3e, data not shown). This suggests that
together with mast cell degranulation, SP treatment also
affects the cellular composition of perifollicular inflammatory
infiltrates in skin affected by AA by increasing the proportion
of CD8 cells.
NK-1R is expressed on CD8þ lymphocytes in skin affected
by AA
To define the cellular targets for SP in skin affected by AA,
double-immunofluorescence staining was performed to
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Figure 2. Increased expression of NEP in skin affected by AA.
The expression of NEP was assessed by (a) semiquantitative RT-PCR and
(b and c) immunohistochemistry in skin affected by AA (spontaneous and
induced by grafting), as well as in non-affected skin from control mice.
(a) Total RNA was isolated from full-thickness skin samples of C3H/HeJ mice
and RT-PCR was performed with primers specific for NEP and b-actin.
Expression of the NEP messenger RNA was markedly increased in
spontaneously developing and experimentally induced AA lesions, compared
to control skin (representative data out of three independent experiments).
(b and c) Weak expression of NEP was seen in the HF outer root sheath in
(b, arrows) control skin. Increase of the NEP expression in the (c, large arrows)
HF outer root sheath and appearance of expression in the (c, small arrows)
inner root sheath. Cell nuclei in (b and c) are visualized by Hoechst 33342.
Bar¼20 mm.
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co-visualize the expression of NK-1R and markers specific for
each type of immune cell seen in the inflammatory infiltrates
around affected HFs (mast cells, CD4þ and CD8þ
lymphocytes, and macrophages). Surprisingly, in skin
affected by AA, mast cells were found to lack NK-1R
expression by the detection method employed here (data
not shown). However, intense NK-1R expression was seen in
CD8þ lymphocytes and MOMA-2þ macrophages infiltrat-
ing the HF epithelium (Figure 4a and c). In addition, weak
NK-1R expression was seen on keratinocytes of the HF outer
and inner root sheaths, but not on CD4þ lymphocytes
(Figure 4b). These data suggest that NK-1R is differentially
expressed by distinct types of immune cells in skin affected
by AA and CD8þ lymphocytes may serve as one of the
targets for the immunoregulatory effects of SP.
SP stimulates the expression of granzyme B in CD8þ cells
To define whether SP treatment results in changes of the
expression of cytotoxicity associated molecules in skin
affected by AA, the expression of granzyme B, an important
marker of activated effector CD8þ cells (Barry and
Bleackley, 2002; Waterhouse et al., 2004), was assessed in
AA-affected and treated by SP or by vehicle control. In skin
affected by AA, granzyme B-positive cells were seen in the
interfollicular dermis and only a few of them showed co-
expression of CD8 antigen (Figure 4d and e). However, after
SP treatment the number of granzyme B/CD8 double-positive
cells was significantly (Po0.01) increased, as compared to
vehicle-treated skin (Figure 4d–f). This suggests that SP
treatment leads to the increase of granzyme B expression in
CD8þ cells and may therefore result in the increase of their
cytotoxic activity in skin affected by AA, especially within the
HF epithelium. Thus, in addition to the effects on skin mast
cells and HF keratinocytes, immunomodulatory activity of SP
in AA lesions may also be realized via stimulation of
granzyme B expression in CD8 cells.
DISCUSSION
It was shown previously that neuropeptides contribute to the
pathogenesis of autoimmune diseases such as rheumatoid
arthritis, systemic lupus erythematosus, and diabetes mellitus
(reviewed by Frieri, 2003). Here, we demonstrate that the
neuropeptide SP is also involved in the regulation of
neuroimmune interactions in the AA lesions that are
characterized by autoimmune inflammation around actively
growing HFs involving T lymphocytes, macrophages, mast
cells, and dendritic cells (Shapiro and Madani, 1999;
McDonagh and Messenger, 2001; McElwee et al., 2003;
Hordinsky and Ericson, 2004; Paus et al., 2005, 2006).
Using the C3H/HeJ mouse model for AA (Sundberg et al.,
1995a; McElwee et al., 2003), we show that the number of
SP-immunoreactive nerve fibers in skin affected by AA
changes significantly compared to non-affected control skin
and shows a strong dependence on the disease progression,
increasing during the early stages of AA development and
decreasing during advanced stages accompanied by hair loss
(Figure 1). In addition, we found that expression of the SP-
degrading enzyme NEP increased in AA-affected skin
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Figure 3. SP treatment in skin affected by AA leads to catagen acceleration, and is accompanied by increase in the number of degranulating mast cells
and CD8þ lymphocytes. C3H/HeJ mice affected by AA were injected intracutaneously with agarose beads soaked either with SP or vehicle. Skin was
harvested 4 weeks after treatment and cryosections were processed for immunohistochemistry and alkaline phosphatase staining for hair cycle staging. Statistical
analyses were performed by Student’s t-test (means7SEM, *Po0.05, **Po0.01). (a) After SP treatment, the percentage of catagen HFs was significantly
increased as compared to vehicle-treated skin. (b) Graph demonstrating the increase in number of mast cells with extensive degranulation after SP treatment,
compared to control. (c and d) After SP treatment, skin mast cells showed markedly increased (d) degranulation, whereas non-degranulating mast cells are seen
in (c) control skin. (e) Graph demonstrating selective increase in number of CD8þ cells infiltrating HF epithelium after SP treatment, whereas number of
CD4þ cells and macrophages remains unchanged, compared to control. (f and g) Numerous CD8þ cells are seen inside of the HF epithelium after SP
treatment (arrows). Bar¼ 20 mm.
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(Figure 2) indicating for active SP degradation. These findings
correlate with increased mast cell degranulation following
the experimental elevation of SP levels by implanting SP-
soaked agarose beads into the skin affected by AA (Figure 3).
Along the same lines SP treatment was found to increase AA
symptoms: catagen HFs are significantly increased and CD8
cell numbers and their expression of the important cytotoxic
mediator granzyme B are markedly elevated (Figures 3 and 4).
SP is a small decapeptide that is rapidly released from
nerve fibers during inflammation and is degraded after
release by NEP (reviewed by Scholzen et al., 1998).
Inflammatory diseases of the skin are frequently associated
with fluctuations in the number of peptidergic nerve fibers
and with their depletion owing to the massive release of
neuropeptides into the sites of inflammation followed by
temporary degeneration of axons (Ostlere et al., 1995). Thus,
an increase in the number of SPþ nerve fibers during early
stages of AA development followed by their decrease in
advanced AA lesions may serve as an indicator for SP release
from nerve fibers during the progression of autoimmune
inflammation and proves SP involvement in the pathogenesis
of AA.
Our data support previous observations that revealed the
presence of SPþ nerve fibers around human HFs affected by
AA (Hordinsky et al., 1995; Hordinsky and Ericson, 1996,
2004; Toyoda et al., 2001). However, statistically significant
alterations in the number of SPþ nerve fibers in human skin
affected by AA versus normal skin have not ever been clearly
demonstrated. Moreover, radioimmunoassay results show
decreased levels of SP in scalp biopsies of AA patients (Rossi
et al., 1997). Although additional studies are required to
further delineate the mechanisms of SP involvement in AA in
humans, data presented here suggest that, similar to mice, SP
levels in human skin affected by AA may also fluctuate
significantly and show a strong correlation with the disease
stage and/or activity.
Also, our data demonstrating the increased expression of
the SP-degrading enzyme NEP in AA-affected skin (Figure 2)
are consistent with results that revealed similar changes in
skin lesions of AA patients (Toyoda et al., 2001). NEP, which
is expressed in the HF outer root sheath during anagen
(Figure 2), is critically important for the regulation of tissue
responsiveness to SP (Grady et al., 1997; Olerud et al., 1999).
As NEP is involved in the termination of proinflammatory
effects of SP in a large number of tissues (Scholzen et al.,
2001; O’Connor et al., 2004; Scholzen and Luger, 2004), the
increased expression of NEP may be considered an important
protective and compensatory response mechanism in skin
affected by AA after massive release of SP from sensory
nerves.
The C3H/HeJ mouse model for AA used here offers a
unique opportunity to dissect neuroimmune interactions
during AA in a defined and timed manner and to help in
elucidating the role and targets for SP during the autoimmune
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Figure 4. Expression of NK-1R and effects of SP on the expression of granzyme B by CD8 lymphocytes in skin affected by AA. Skin of C3H/HeJ mice affected
by AA was harvested and cryosections were processed for double immunovisualization of NK-1R and CD8þ , CD4þ , or MOMA-2. The expression of granzyme
B, an important marker of activated effector CD8þ cells, was assessed in SP-treated and control AA skin. (a) Expression of NK-1R on CD8þ lymphocytes
infiltrating the HF epithelium (large arrows). Some CD8þ cells do not express NK-1R (arrowheads) and NK-1Rþ /CD8-negative cells are seen in perifollicular
dermis (small arrows). (b) Lack of NK-1R expression on CD4þ lymphocytes (arrowheads). NK-1R-expressing cells are also seen in the dermis (arrows).
(c) Expression of NK-1R on subset of MOMA-2þ macrophages (large arrows). Single CD8þ and MOMA-2þ cells are shown by small arrows and arrowheads,
respectively. (d) Graph demonstrating the increase in number of CD8þ cells expressing granzyme B after SP treatment, compared to control. Student’s t-test,
means7SEM, **Po0.01. (e) Single granzyme Bþ cells (large arrow) and numerous CD8þ cells (small arrows) are seen in the interfollicular dermis of
control skin. (f) After SP treatment, the number of granzyme B/CD8 double-positive cells (yellow fluorescence, large arrows) was significantly increased.
CD8þ cells that lack expression of granzyme B are indicated by small arrows. Cell nuclei are counterstained with Hoechst 33342. Bar¼20 mm. Abbreviations:
DER – dermis; HF – hair follicle.
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response. Our data on skin response to SP administration and
on NK-1R expression suggest that SP may target at least four
distinct cell populations in skin affected by AA: hair follicle
keratinocytes, mast cells, CD8 lymphocytes, and macro-
phages (Figures 3 and 4). The increase in hair follicle
regression after SP treatment observed here (Figure 3) is
consistent with previously published results that show
premature termination of active hair growth (anagen) in
normal mice after capsaicin or SP treatment (Maurer et al.,
1997; Arck et al., 2003). However, mechanisms of these
effects remains to be further clarified: in particular, it is
unclear whether SP directly affects HF keratinocytes and
induces HF regression in AA, or whether this effect is partially
or fully mast cell dependent.
Because mast cell degranulation can also induce HF
entering into catagen (Maurer et al., 1997), mast cells may
indeed contribute to the accelerated catagen development
seen in AA-affected skin after SP treatment. Although we
were not able to detect NK-1R expression on mast cells in
AA-affected skin with the detection method applied here,
several observations suggest that SP may induce mast cell
degranulation through a receptor-independent mechanism
(Foreman, 1987; Saban et al., 2002; Kleij et al., 2003) or
indirectly, via release of cytokines (Ansel et al., 1993) and
other modulators of mast cell activity from inflammatory cells
(reviewed by Paus et al., 2006).
Mast cells, therefore, may be considered important players
involved in neuroimmune interactions modulating the
development of AA. The marked increase of mast cell
degranulation after SP treatment in AA skin (Figure 3) may
be considered one of the features of neurogenic inflamma-
tion. It was shown previously that neurogenic inflammation
in skin accompanied by extensive mast cell degranulation
can be observed after exposure of mice to stress (Arck et al.,
2003), and this response can be suppressed by administration
of NK-1R antagonists and/or nerve growth factor-neutralizing
antibodies (Arck et al., 2001, 2003; Peters et al., 2005).
Psycho-emotional stress is considered one of the important
factors that trigger AA development in humans (Gupta et al.,
1997; Misery and Rousset, 2001). It remains to be explored,
however, whether AA development in mice may be affected
by stress exposure and whether or not this effect is mast cell
dependent.
In addition to hair follicle keratinocytes and mast cells,
CD8 lymphocytes may be considered a target for SP in AA-
affected skin: CD8 cells infiltrating HFs express NK-1R, their
number and expression of granzyme B are significantly
increased after SP administration (Figures 3 and 4). These
observations are in good agreement with data demonstrating
the stimulatory effects of SP on cell adhesion and lymphocyte
recruitment into inflamed tissue (Lindsey et al., 2000; Kang
et al., 2004). Furthermore, SP treatment exacerbates the
severity of other experimental autoimmune inflammatory
diseases such as arthritis, which is T-cell dependent (Colpaert
et al., 1983). It has been shown previously that SP can induce
a large variety of responses in lymphocytes and that it
stimulates the release of proinflammatory cytokines from
these cells (O’Connor et al., 2004). Our data link, the
proinflammatory effects of SP to the granzyme B expression
in CD8þ cells (Figure 4). This observation is consistent with
reports demonstrating the increase of cytotoxic activity of
natural killer cells after SP administration (Lang et al., 2003)
and suggests a new mechanism in the controlling CD8
effector functions by SP.
Taken together, our data suggest that by interacting with
distinct cellular targets in AA-affected skin, SP plays an
important role in the pathogenesis of AA. Similar to other
inflammatory conditions, SP modulates neurogenic inflam-
mation and autoimmune response in AA at least in part by
stimulating mast cell degranulation and CD8þ cell accu-
mulation in inflammatory lesions and by increasing their
cytotoxicity. However, additional efforts employing pharma-
cological and genetic approaches are required to fully
understand the role of SP and other neuropeptides in the
pathobiology of autoimmune responses to HF antigens,
which, eventually, may result in the development of new
approaches for the treatment of AA and other autoimmune
disorders.
MATERIALS AND METHODS
Mice and experimental treatment protocols
All animal experiments were conducted in accordance with current
federal, state, and institutional guidelines. C3H/HeJ mice affected by
AA (Sundberg et al., 1995a, b) and non-affected control mice were
obtained from the Jackson Laboratory (Bar-Harbor, ME). To induce
AA, skin from C3H/HeJ mice that had developed spontaneous AA
lesions was grafted onto the back of non-affected C3H/HeJ mice, as
described previously (McElwee et al., 1998). Age-matched mice at
spontaneous anagen VI (non-affected by AA, n¼ 5), as well as mice
with spontaneous AA lesions (n¼ 10) and mice with early and
advanced stages of induced AA (3–4 and 8–12 weeks after grafting,
respectively, n¼ 25) were used for experiments.
Eight weeks after grafting, C3H/HeJ mice that had developed AA
lesions (n¼ 15) were injected intracutaneously either with agarose
beads (Biorad Laboratories Inc., Hercules, CA), soaked with SP
(1 mg/ml, Sigma, St Louis, MO), or with vehicle (normal mouse
serum, Sigma) (Botchkarev et al., 2001). All mice were sacrificed
after 4 weeks of observation and skin samples were collected from
the control (n¼ 5) and experimental (n¼ 10) groups of mice, as well
as from untreated animals affected by AA (n¼ 10), according to
previously described protocols (Muller-Rover et al., 2001). As
inflammatory cell infiltrates and the number of immune cells
attacking the HFs in AA reach their maximal extent around late
anagen HFs and decrease strongly after HFs enter catagen (Sundberg
et al., 1995a; McElwee et al., 2003), only skin areas that contained
late anagen–early catagen HFs were selected for histomorphometry
of immune cells (CD4þ and CD8þ lymphocytes, macrophages,
and mast cells) after SP treatment.
ELISA and semiquantitative RT-PCR
For protein extraction, full-thickness skin samples of C3H/HeJ mice,
dissected at the level of the subcutis just below the panniculus
carnosus of AA-affected and non-affected mice were pulverized in
liquid nitrogen. Skin was treated with lysis buffer (0.5 ml/100 mg;
50 mmol/l Tris/HCl, pH 8.0, 150 mmol/l NaCl, 1 mmol/l EDTA,
1 mmol/l phenylmethylsulfonyl fluoride, 5 mmol/l iodacetamid,
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10 mg/ml aprotinin, 0.2% SDS, 1% Nonidet, and 1% Triton X-100),
all obtained from Sigma and lysed by sonication. After 1-hour
shaking at 41C, the mixture was sonicated again. The solution was
centrifuged for 30 minutes at 14,000 r.p.m. at 41C, and the super-
natants were frozen and stored at 801C. For quantification of SP
protein, a commercially available ELISA-kit was used (R&D Systems
Inc., Minneapolis, MN) according to the manufacturer’s instructions
(Botchkarev et al., 1998, 1999b).
Semiquantitative RT-PCR was performed to assess the expression
of the NEP and b-actin transcripts. Total RNA was isolated from full-
thickness skin samples of AA-affected and non-affected C3H/HeJ
mice using Trizol LS reagent (Invitrogen, San Diego, CA). Com-
plementary DNA was synthesized by reverse transcription of total
RNA, using a complementary DNA synthesis kit (Invitrogen). The
following primer sets were used: NEP, 50-TGG GAC TAC ATC AGA
AAC TGC-30 and 50-CTG ATT TCG GCC TGA GGA-30, 460 bp; b-
actin, 50-TGG AAT CCT GTG GCA TCC ATG AAA C-30 and 50-TAA
AAC GCA GCT CAG TAA CAG TCC G-30, 520 bp. Primers used
were designed according to the reported sequences in the GenBank
databases. Amplification was performed using Taq polymerase
(Invitrogen) over 35 cycles, using an automated thermal cycler.
Each cycle consisted of the denaturing at 941C (1 minute), annealing
at 601C (45 seconds), and extension at 721C (45 seconds). PCR
products were analyzed by agarose gel electrophoresis, stained with
ethidium bromide, and visualized under UV light (Sharov et al.,
2003b, 2004, 2005).
Immunohistochemistry
Cryostat sections, fixed in acetone (201C, 10 minutes), were used to
analyze the expression of NEP, NK-1R, lymphocyte markers CD4/
CD8, macrophage marker MOMA-2, and granzyme B antigen in
non-affected skin of control C3H/HeJ mice and in AA-affected skin.
Perfusion fixation with formaldehyde was used for visualizing SP-
immunoreactive nerve fibers in skin, as described previously
(Botchkarev et al., 1997a, b). Rabbit polyclonal antibodies were
used for the analysis of SP, NEP and NK-1R expression (Chemicon,
Temecula, CA). CD4þ and CD8þ T cells were detected by rat
mAbs (Pharmingen, San Diego, CA), and rabbit polyclonal antisera
were used to visualize MOMA-2 (Nibbering et al., 1987; Serotec,
Kidlington, Oxford, UK) and granzyme B (Lab Vision, Fremont, CA).
All sections were incubated with primary antisera overnight at room
temperature, followed by incubation with TRITC- or FITC-con-
jugated F(ab)2 fragments of goat IgG (Jackson ImmunoResearch,
West Grove)for 45 minutes at 371C. Double immunovisualization of
the NK-1R and CD8, CD4 or MOMA-2, or granzyme B and CD8
antigens was performed according to the protocols described
previously (Botchkarev et al., 1999a, 2000; Sharov et al., 2003a).
Mast cells were visualized by FITC–avidin staining, as described
previously (Botchkarev et al., 1997b). Sections were counterstained
with Hoechst 33342 (Sigma). The same investigator analyzed all
sections used for the evaluation of cell numbers in a blinded manner.
Photo-documentation was performed by multicolor confocal micro-
scopy (Zeiss, Thornwood, NY) and digital image analysis system
(Pixera, Los Gatos, CA).
Histomorphometry and statistical analysis
For the precise identification of the defined stages of HF cycling,
histochemical detection of endogenous alkaline phosphatase activity
was employed, because this technique allows for the visualization of
dermal papilla morphology, a useful marker for staging HF cycling
(Muller-Rover et al., 2001). The percentages of HFs in distinct
catagen stages were assessed and calculated in SP-treated and
control mice. All evaluations were performed on the basis of
accepted morphologic criteria of HF classification (Muller-Rover
et al., 2001). Only every tenth cryosection was used for analysis in
order to exclude the repetitive evaluation of the same HF, and 2–3
cryosections were assessed from each animal. Altogether, 250–300
HFs in 50–60 microscopic fields, derived from five animals
(approximately 50–60 follicles per animal) of distinct age were
analyzed and compared to a corresponding number of HFs from
appropriate, age-matched wild-type mice. Number of SPþ nerve
fibers in skin during early and advanced stages of AA was assessed,
as described previously (Peters et al., 2001). The number of immune
cells (lymphocytes, macrophages, and mast cells) was assessed in
skin cryosections of SP-treated and control animals, as described
previously (Hoffman et al., 1996; Freyschmidt-Paul et al., 1999b). In
total, 40–50 such measurements were performed in 50–60 micro-
scopic fields derived from five animals per experimental and control
group. All sections were analyzed at  200 to  400 magnification,
and means7SEM were calculated from pooled data. Differences
were judged as significant if the P-value was lower than 0.05, as
determined by the independent Student’s t-test for unpaired samples.
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